Ceralasertib
- Generic Name
- Ceralasertib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N6O2S
- CAS Number
- 1352226-88-0
- Unique Ingredient Identifier
- 85RE35306Z
- Background
Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT06929260
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Phase 2
Not yet recruiting
- Conditions
- Lung Small Cell Carcinoma, I SubtypeLung Small Cell Carcinoma, N SubtypeLung Small Cell Carcinoma, P SubtypeExtensive Stage Lung Small Cell CarcinomaLung Small Cell Carcinoma, A Subtype
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: Platinum CompoundProcedure: Positron Emission TomographyRadiation: Thoracic Radiation Therapy
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 900
- Registration Number
- NCT06769126
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
Phase 1
Not yet recruiting
- Conditions
- Neoplasm
- Interventions
- Drug: [14C] AZD6738
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06754761
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography Test
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 630
- Registration Number
- NCT06732401
Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL)
Phase 2
Not yet recruiting
- Conditions
- Non Small Cell Lung Cancer NSCLC
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Mario Negri Institute for Pharmacological Research
- Target Recruit Count
- 21
- Registration Number
- NCT06680050
- Locations
- 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, Italy
🇮🇹Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
🇮🇹IRCCS Ospedale Policlinico San Martino, Genova, Genova, Italy
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Phase 2
Active, not recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT05941897
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Phase 2
Recruiting
- Conditions
- Triple Negative Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
- Target Recruit Count
- 37
- Registration Number
- NCT05582538
- Locations
- 🇮🇹
ASST Papa Giovanni XXIII, Bergamo, Italy
🇮🇹IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale", Napoli, Italy
🇮🇹Azienda U.S.L. - IRCCS di Reggio Emilia, Reggio Emilia, Italy
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT05514132
- Locations
- 🇨🇳
Research Site, Shandong, China
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT05469919
- Locations
- 🇯🇵
Research Site, Chuo-ku, Japan
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Phase 3
Active, not recruiting
- Conditions
- Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 594
- Registration Number
- NCT05450692
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath